Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial
Open Access
- 25 February 2021
- Vol. 11 (2), e042953
- https://doi.org/10.1136/bmjopen-2020-042953
Abstract
Introduction Survival in men diagnosed with de novo synchronous metastatic prostate cancer has increased following the use of upfront systemic treatment, using chemotherapy and other novel androgen receptor targeted agents, in addition to standard androgen deprivation therapy (ADT). Local cytoreductive and metastasis-directed interventions are hypothesised to confer additional survival benefit. In this setting, IP2-ATLANTA will explore progression-free survival (PFS) outcomes with the addition of sequential multimodal local and metastasis-directed treatments compared with standard care alone. Methods A phase II, prospective, multicentre, three-arm randomised controlled trial incorporating an embedded feasibility pilot. All men with new histologically diagnosed, hormone-sensitive, metastatic prostate cancer, within 4 months of commencing ADT and of performance status 0 to 2 are eligible. Patients will be randomised to Control (standard of care (SOC)) OR Intervention 1 (minimally invasive ablative therapy to prostate±pelvic lymph node dissection (PLND)) OR Intervention 2 (cytoreductive radical prostatectomy±PLND OR prostate radiotherapy±pelvic lymph node radiotherapy (PLNRT)). Metastatic burden will be prespecified using the Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease (CHAARTED) definition. Men with low burden disease in intervention arms are eligible for metastasis-directed therapy, in the form of stereotactic ablative body radiotherapy (SABR) or surgery. Standard systemic therapy will be administered in all arms with ADT±upfront systemic chemotherapy or androgen receptor agents. Patients will be followed-up for a minimum of 2 years. Primary outcome: PFS. Secondary outcomes include predictive factors for PFS and overall survival; urinary, sexual and rectal side effects. Embedded feasibility sample size is 80, with 918 patients required in the main phase II component. Study recruitment commenced in April 2019, with planned follow-up completed by April 2024. Ethics and dissemination Approved by the Health Research Authority (HRA) Research Ethics Committee Wales-5 (19/WA0005). Study results will be submitted for publication in peer-reviewed journals. Trial registration number NCT03763253; ISCRTN58401737Funding Information
- Wellcome Trust (204998/Z/16/Z)
This publication has 62 references indexed in Scilit:
- pT0 Prostate Cancer: Predictive Clinicopathologic Features in an American PopulationCurrent Urology, 2013
- Circulating microRNAs as potential new biomarkers for prostate cancerBritish Journal of Cancer, 2013
- The metastatic niche and stromal progressionCancer and Metastasis Reviews, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaThe New England Journal of Medicine, 2012
- Clinical implications of cancer self-seedingNature Reviews Clinical Oncology, 2011
- Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrowJCI Insight, 2011
- Oligometastases revisitedNature Reviews Clinical Oncology, 2011
- Tumor Self-Seeding by Circulating Cancer CellsCell, 2009
- Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical RecurrenceClinical Cancer Research, 2009
- Impact of Previous Local Treatment for Prostate Cancer on Subsequent Metastatic DiseaseJournal of Urology, 2002